# Dayton Clinical Oncology Program

> **NIH NIH UG1** · DAYTON CLINICAL ONCOLOGY PROGRAM · 2021 · $950,647

## Abstract

Dayton Clinical Oncology Program (Dayton NCORP): Project Summary/Abstract
The Dayton Clinical Oncology Program, hereafter referred to as “Dayton NCORP”, was incorporated in
the State of Ohio in 1983 as a non-profit 501c3 corporation, and one of the original NCI Community
Clinical Oncology Programs (CCOP). At that time, a consortium agreement was established between
Dayton NCORP, the Dayton area adult hospitals, and Wright State University (WSU). A governing
board was established and corporate bylaws were developed.
Kettering Medical Center was the original grantee organization until 2001, when Dayton NCORP
subcontracted with WSU for human resources, technical support, and financial oversight. Dayton
NCORP contracts with a local accounting firm to conduct an annual external A-133 financial audit. In
2014, Dayton Clinical Oncology Program, was successfully awarded an NCI Community Oncology
Research Program (NCORP) Community Site five-year grant.
Currently, the Dayton NCORP Board of Directors is led by Principal Investigator Howard M. Gross,
M.D. as Chairperson, Dr. John Haluschak, Associate Principal Investigator and Vice Chairperson of the
Board, and Mary Ontko, BSN, RN, OCN, President of the Board and Chief Executive Officer. Other
directors represent consortium hospital-members. The Board meets semi-annually to review budget
reports and program activities.
Fifty-four physicians, representing medical, surgical, gynecological oncology and radiation therapy, 20
hospital-based oncology research nurses, funded by our member hospitals, and 13 office staff, funded
by the NCI grant, make up the research team. The office staff includes directors for quality, regulatory,
and research projects, along with research coordinators, a pharmacy technician, an administrative
specialist, and a research associate. Dayton NCORP is expanding; three hospitals in Youngstown, in
northeast Ohio, have signed a Consortium Agreement and are undergoing the first steps of the process
to join Dayton NCORP, and other sites have expressed interest in joining.
Dayton NCORP is currently seeking continued funding through the six-grant year period running August
1, 2019 through July 31, 2025. Continued funding will allow the consortium to continue the Dayton
NCORP mission To reduce cancer incidence and mortality through improved treatment and prevention
by offering national state-of-the-art cancer research to the local communities.

## Key facts

- **NIH application ID:** 10225452
- **Project number:** 5UG1CA189957-08
- **Recipient organization:** DAYTON CLINICAL ONCOLOGY PROGRAM
- **Principal Investigator:** Howard M Gross
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $950,647
- **Award type:** 5
- **Project period:** 2014-08-01 → 2025-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10225452

## Citation

> US National Institutes of Health, RePORTER application 10225452, Dayton Clinical Oncology Program (5UG1CA189957-08). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10225452. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*